1. Home
  2. TGHL vs BIVI Comparison

TGHL vs BIVI Comparison

Compare TGHL & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGHL

The GrowHub Limited Class A Ordinary Shares

N/A

Current Price

$0.40

Market Cap

10.5M

Sector

Technology

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.56

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGHL
BIVI
Founded
2020
2013
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
8.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
TGHL
BIVI
Price
$0.40
$1.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.5K
53.6K
Earning Date
05-18-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.82
52 Week High
$3.80
$9.09

Technical Indicators

Market Signals
Indicator
TGHL
BIVI
Relative Strength Index (RSI) 49.53 63.09
Support Level $0.33 $1.52
Resistance Level $0.38 $1.68
Average True Range (ATR) 0.03 0.09
MACD 0.01 0.02
Stochastic Oscillator 60.09 96.23

Price Performance

Historical Comparison
TGHL
BIVI

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: